Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MiNK Therapeutics
(NASDAQ:INKT)
Intraday
$0.9699
0.0198
[2.08%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$0.9699
0.0198
[2.08%]
Last update: 9:29AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 14 days from now on Tue May 14th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for MiNK Therapeutics Stock (NASDAQ:INKT)
MiNK Therapeutics Stock (NASDAQ: INKT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 08, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Apr 8, 2024, 12:31PM
MiNK Therapeutics Announces Preclinical Activity Of MiNK-215 Against Colorectal Cancer Liver Metastases At AACR
Benzinga Newsdesk
-
Apr 8, 2024, 12:01PM
Friday, April 05, 2024
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Apr 5, 2024, 1:06PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Apr 5, 2024, 8:09AM
Thursday, March 21, 2024
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk
-
Mar 21, 2024, 11:27AM
MiNK Therapeutics Q4 EPS $(0.16) Misses $(0.15) Estimate
Benzinga Newsdesk
-
Mar 21, 2024, 7:06AM
Earnings Scheduled For March 21, 2024
Benzinga Insights
-
Mar 21, 2024, 6:15AM
Wednesday, March 20, 2024
Earnings Outlook For MiNK Therapeutics
Benzinga Insights
-
Mar 20, 2024, 12:01PM
Wednesday, March 06, 2024
MiNK Announces Preclinical Data Showcasing Activity Of MiNK-215 Against Colorectal Cancer Liver Metastases At AACR 2024
Benzinga Newsdesk
-
Mar 6, 2024, 8:37AM
Wednesday, February 14, 2024
MiNK Therapeutics, Inc. Announces First Refractory Gastric Cancer Patient Dosed In Phase 2 Trial With Novel Combination Of Co's Allogeneic INKT Cell Therapy And Agenus' Botensilimab And Balstilimab
Benzinga Newsdesk
-
Feb 14, 2024, 8:13AM
Wednesday, February 07, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Feb 7, 2024, 4:31PM
Tuesday, February 06, 2024
MiNK Therapeutics' AgenT-797 Presents Results In The Treatment Of Severe Acute Respiratory Distress, Published In Nature Communications
Benzinga Newsdesk
-
Feb 6, 2024, 8:17AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Feb 6, 2024, 8:06AM
Tuesday, January 30, 2024
MiNK Therapeutics' MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
Benzinga Newsdesk
-
Jan 30, 2024, 8:12AM
Wednesday, December 20, 2023
MiNK Therapeutics And ImmunoScape Collaborate To Accelerate Novel TCR Identification And Therapeutic Development
Benzinga Newsdesk
-
Dec 20, 2023, 7:32AM
Thursday, November 09, 2023
MiNK Therapeutics Q3 2023 EPS $(0.15) Beats $(0.18) Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 7:05AM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Friday, November 03, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Nov 3, 2023, 5:31PM
MiNK Therapeutics Presents Clinical Activity And Long-Term Persistence Of Allogeneic iNKT Cells In Solid Tumors At SITC 2023
Benzinga Newsdesk
-
Nov 3, 2023, 12:08PM
Tuesday, October 17, 2023
Sacks Parente Golf And 3 Other Stocks Under $2 Insiders Are Buying
Lisa Levin
-
Oct 17, 2023, 8:13AM
Monday, October 09, 2023
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
Lisa Levin
-
Oct 9, 2023, 8:51AM
Wednesday, October 04, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Oct 4, 2023, 1:31PM
Tuesday, August 29, 2023
MiNK Therapeutics 10% Owner Makes $281K Stock Purchase
Benzinga Insights
-
Aug 29, 2023, 11:02AM
Thursday, August 10, 2023
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 12:01PM
MiNK Therapeutics Q2 EPS $(0.18) Beats $(0.20) Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 7:31AM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Thursday, June 22, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jun 22, 2023, 1:38PM
Monday, May 22, 2023
MiNK Presents Clinical Data On Allogeneic iNKT Cells In Severe Respiratory Distress At The American Thoracic Society International Conference
Benzinga Newsdesk
-
May 22, 2023, 8:41AM
Monday, May 15, 2023
Over $1M Bet On This Basic Materials Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
May 15, 2023, 7:41AM
Friday, May 12, 2023
The Latest Analyst Ratings for MiNK Therapeutics
Benzinga Insights
-
May 12, 2023, 9:01AM
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Raises Price Target to $10
Benzinga Newsdesk
-
May 12, 2023, 6:52AM
Thursday, May 11, 2023
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Recap: MiNK Therapeutics Q1 Earnings
Benzinga Insights
-
May 11, 2023, 8:17AM
MiNK Therapeutics Q1 EPS $(0.17) Beats $(0.24) Estimate
Benzinga Newsdesk
-
May 11, 2023, 8:02AM
Friday, May 05, 2023
First Foundation And 2 Other Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
May 5, 2023, 7:35AM
Thursday, May 04, 2023
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
May 4, 2023, 9:06AM
Wednesday, April 19, 2023
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Apr 19, 2023, 6:22AM
Tuesday, April 18, 2023
MiNK Therapeutics Announces Clinical Data Of Allogeneic iNKT Cells In Solid Tumor Cancers At The AACR Annual Meeting
Happy Mohamed
-
Apr 18, 2023, 1:38PM
Thursday, March 30, 2023
Agenus Announces Dividend Of 5M Shares Of Its Subsidiary, MiNK Therapeutics, To Shareholders Of Agenus As Of April 17, 2023
Happy Mohamed
-
Mar 30, 2023, 8:49AM
Wednesday, March 22, 2023
Evercore ISI Group Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk
-
Mar 22, 2023, 11:33AM
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Mar 22, 2023, 6:20AM
Tuesday, March 21, 2023
MiNK Therapeutics Q4 EPS $(0.23) Misses $(0.21) Estimate; Cash Balance Of $19.6M
Benzinga Newsdesk
-
Mar 21, 2023, 8:03AM
Earnings Scheduled For March 21, 2023
Benzinga Insights
-
Mar 21, 2023, 6:46AM
Monday, March 20, 2023
Preview: MiNK Therapeutics's Earnings
Benzinga Insights
-
Mar 20, 2023, 11:01AM
Friday, March 17, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Mar 17, 2023, 9:06AM
Wednesday, March 15, 2023
MiNK Therapeutics To Present Updated Clinical Data Of allo-iNKT Cell Therapy In Solid Tumors At AACR Annual Meeting On Tuesday April 18, 2023
Happy Mohamed
-
Mar 15, 2023, 8:47AM
Wednesday, January 04, 2023
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Jan 4, 2023, 1:17PM
Monday, November 14, 2022
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Lisa Levin
-
Nov 14, 2022, 2:35AM
Thursday, November 03, 2022
Mink Therapeutics Inc Files for Mixed Shelf of Up to $50M
Charles Gross
-
Nov 3, 2022, 5:09PM
MiNK Therapeutics Reports Cash, Cash Equivalents As Of Sept. 30, 2022 $24.158M
Benzinga Newsdesk
-
Nov 3, 2022, 7:57AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
